Identification of hub genes and discovery of promising compounds in gastric cancer based on bioinformatics analysis

References

• 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
  MedlineGoogle Scholar
• 2. Verdecchia A, Francisci S, Brenner H et al. Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol. 8(9), 784–796 (2007).
  MedlineGoogle Scholar
• 3. Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. Nat. Rev. Dis. Primers 3, 17036 (2017).
  MedlineGoogle Scholar
• 4. Chiurillo MA. Role of the Wnt/beta-catenin pathway in gastric cancer: an in-depth literature review. World J. Exp. Med. 5(2), 84–102 (2015).
  MedlineGoogle Scholar
• 5. Maeda M, Moro H, Ushijima T. Mechanisms for the induction of gastric cancer by Helicobacter pylori infection: aberrant DNA methylation pathway. Gastric Cancer 20(Suppl. 1), 8–15 (2017).
  Medline CASGoogle Scholar
• 6. Sadjadi A, Derakhshan MH, Yazdanbod A et al. Neglected role of hookah and opium in gastric carcinogenesis: a cohort study on risk factors and attributable fractions. Int. J. Cancer 134(1), 181–188 (2014).
  MedlineGoogle Scholar
• 7. Smyth EC, Turner NC, Pearson A et al. Phase II study of AZD4547 in FGFR amplified tumours: gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results. J. Clin. Oncol. 34(4), (2016).
  Google Scholar
• 8. Lee J, Bendell JC, Rha SY et al. Antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-selective monoclonal antibody, in patients with FGFR2b+gastric cancer and advanced solid tumors. J. Clin. Oncol. 34(15), 2502 (2016).
  Google Scholar
• 9. Jin Y, Yang Y. Identification and analysis of genes associated with head and neck squamous cell carcinoma by integrated bioinformatics methods. Mol. Genet. Genomic Med. 7(8), e857 (2019).
  MedlineGoogle Scholar
• 10. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 339(6127), 1546–1558 (2013).
  Medline CASGoogle Scholar
• 11. Li H, Liu L, Zhuang J et al. Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis. Mol. Genet. Genomic Med. 7(9), e851 (2019).
  MedlineGoogle Scholar
• 12. Yang F, Zhai Z, Luo X et al. Bioinformatics identification of key candidate genes and pathways associated with systemic lupus erythematosus. Clin. Rheumatol. doi:10.1007/s10067-019-04751-7 (2019) (Epub ahead of print).
  Google Scholar
• 13. Barrett T, Wilhite SE, Ledoux P et al. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 41(Database issue), D991–995 (2013).
  Medline CASGoogle Scholar
• 14. Huang Da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4(1), 44–57 (2009).
  Medline CASGoogle Scholar
• 15. Szklarczyk D, Gable AL, Lyon D et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47(D1), D607–D613 (2019).
  Medline CASGoogle Scholar
• 16. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45(W1), W98–W102 (2017).
  Medline CASGoogle Scholar
• 17. Uhlen M, Fagerberg L, Hallstrom BM et al. Proteomics. Tissue-based map of the human proteome. Science 347(6220), 1260419 (2015).
  MedlineGoogle Scholar
• 18. Lamb J, Crawford ED, Peck D et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes and disease. Science 313(5795), 1929–1935 (2006).
  Medline CASGoogle Scholar
• 19. Lamb J. The Connectivity Map: a new tool for biomedical research. Nat. Rev. Cancer 7(1), 54–60 (2007).
  Medline CASGoogle Scholar
• 20. Davis AP, Grondin CJ, Johnson RJ et al. The comparative toxicogenomics database: update 2019. Nucleic Acids Res. 47(D1), D948–D954 (2019).
  Medline CASGoogle Scholar
• 21. Perkel JM. How bioinformatics tools are bringing genetic analysis to the masses. Nature 543(7643), 137–138 (2017).
  Medline CASGoogle Scholar
• 22. Jiang P, Liu XS. Big data mining yields novel insights on cancer. Nat. Genet. 47(2), 103–104 (2015).
  Medline CASGoogle Scholar
• 23. Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK. Extracellular matrix structure. Adv. Drug Deliv. Rev. 97, 4–27 (2016).
  Medline CASGoogle Scholar
• 24. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat. Rev. Mol. Cell Biol. 15(12), 786–801 (2014).
  Medline CASGoogle Scholar
• 25. Walker C, Mojares E, Del Rio Hernandez A. Role of extracellular matrix in development and cancer progression. Int. J. Mol. Sci. 19(10), (2018).
  Google Scholar
• 26. Shang C, Sun L, Zhang J et al. Silence of cancer susceptibility candidate 9 inhibits gastric cancer and reverses chemoresistance. Oncotarget 8(9), 15393–15398 (2017).
  MedlineGoogle Scholar
• 27. Tian L, Zhao Z, Xie L, Zhu J. MiR-361-5p suppresses chemoresistance of gastric cancer cells by targeting FOXM1 via the PI3K/Akt/mTOR pathway. Oncotarget 9(4), 4886–4896 (2018).
  MedlineGoogle Scholar
• 28. Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for cancer treatment. Annu. Rev. Med. 67, 11–28 (2016).
  Medline CASGoogle Scholar
• 29. Gan L, Meng J, Xu M et al. Extracellular matrix protein 1 promotes cell metastasis and glucose metabolism by inducing integrin beta4/FAK/SOX2/HIF-1alpha signaling pathway in gastric cancer. Oncogene 37(6), 744–755 (2018).
  Medline CASGoogle Scholar
• 30. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J. Cell. Physiol. 182(3), 311–322 (2000).
  Medline CASGoogle Scholar
• 31. Li LT, Jiang G, Chen Q, Zheng JN. Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol. Med. Rep. 11(3), 1566–1572 (2015).
  Medline CASGoogle Scholar
• 32. Sugianto J, Sarode V, Peng Y. Ki-67 expression is increased in p16-expressing triple-negative breast carcinoma and correlates with p16 only in p53-negative tumors. Hum. Pathol. 45(4), 802–809 (2014).
  Medline CASGoogle Scholar
• 33. Li P, Xiao ZT, Braciak TA, Ou QJ, Chen G, Oduncu FS. Association between Ki67 index and clinicopathological features in colorectal cancer. Oncol. Res. Treat. 39(11), 696–702 (2016).
  Medline CASGoogle Scholar
• 34. Tang J, Gui C, Qiu S, Wang M. The clinicopathological significance of Ki67 in papillary thyroid carcinoma: a suitable indicator? World J. Surg. Oncol. 16(1), 100 (2018).
  MedlineGoogle Scholar
• 35. Luo G, Hu Y, Zhang Z et al. Clinicopathologic significance and prognostic value of Ki-67 expression in patients with gastric cancer: a meta-analysis. Oncotarget 8(30), 50273–50283 (2017).
  MedlineGoogle Scholar
• 36. Huang G, Chen S, Wang D et al. High Ki67 expression has prognostic value in surgically-resected T3 gastric adenocarcinoma. Clin. Lab. 62(1–2), 141–153 (2016).
  Medline CASGoogle Scholar
• 37. Ko GH, Go SI, Lee WS et al. Prognostic impact of Ki-67 in patients with gastric cancer-the importance of depth of invasion and histologic differentiation. Medicine (Baltimore) 96(25), e7181 (2017).
  Medline CASGoogle Scholar
• 38. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat. Rev. Cancer 10(12), 825–841 (2010).
  Medline CASGoogle Scholar
• 39. Combes G, Alharbi I, Braga LG, Elowe S. Playing polo during mitosis: PLK1 takes the lead. Oncogene 36(34), 4819–4827 (2017).
  Medline CASGoogle Scholar
• 40. Raab M, Sanhaji M, Matthess Y et al. PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells. Nat. Commun. 9(1), 1106 (2018).
  MedlineGoogle Scholar
• 41. Ren Y, Bi C, Zhao X et al. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas. J. Clin. Invest. 128(12), 5517–5530 (2018).
  MedlineGoogle Scholar
• 42. Hassan QN 2nd, Alinari L, Byrd JC. PLK1: a promising and previously unexplored target in double-hit lymphoma. J. Clin. Invest. 128(12), 5206–5208 (2018).
  MedlineGoogle Scholar
• 43. Gutteridge RE, Ndiaye MA, Liu X, Ahmad N. Plk1 inhibitors in cancer therapy: from laboratory to clinics. Mol. Cancer Ther. 15(7), 1427–1435 (2016).
  Medline CASGoogle Scholar
• 44. Lian G, Li L, Shi Y et al. BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells. Int. J. Oncol. 52(3), 804–814 (2018).
  Medline CASGoogle Scholar
• 45. Dang SC, Fan YY, Cui L, Chen JX, Qu JG, Gu M. PLK1 as a potential prognostic marker of gastric cancer through MEK-ERK pathway on PDTX models. Onco Targets Ther. 11, 6239–6247 (2018).
  Medline CASGoogle Scholar
• 46. Cai XP, Chen LD, Song HB, Zhang CX, Yuan ZW, Xiang ZX. PLK1 promotes epithelial-mesenchymal transition and metastasis of gastric carcinoma cells. Am. J. Transl. Res. 8(10), 4172–4183 (2016).
  Medline CASGoogle Scholar
• 47. Otsu H, Iimori M ando K et al. Gastric cancer patients with high PLK1 expression and DNA aneuploidy correlate with poor prognosis. Oncology 91(1), 31–40 (2016).
  Medline CASGoogle Scholar
• 48. Exposito JY, Valcourt U, Cluzel C, Lethias C. The fibrillar collagen family. Int. J. Mol. Sci. 11(2), 407–426 (2010).
  Medline CASGoogle Scholar
• 49. Ma HP, Chang HL, Bamodu OA et al. Collagen 1A1 (COL1A1) is a reliable biomarker and putative therapeutic target for hepatocellular carcinogenesis and metastasis. Cancers (Basel) 11(6), 786 (2019).
  CASGoogle Scholar
• 50. Wang Q, Yu JH. MiR-129-5p suppresses gastric cancer cell invasion and proliferation by inhibiting COL1A1. Biochem. Cell Biol. 96(1), 19–25 (2018).
  Medline CASGoogle Scholar
• 51. Shi Y, Wang JH, Xin ZY, Duan ZP, Wang GQ, Li F. Transcription factors and microrna-co-regulated genes in gastric cancer invasion in ex vivo. PLoS ONE 10(4), e0122882 (2015).
  MedlineGoogle Scholar
• 52. Li J, Ding YM, Li AQ. Identification of COL1A1 and COL1A2 as candidate prognostic factors in gastric cancer. World J. Surg. Oncol. 14(1), 297 (2016).
  MedlineGoogle Scholar
• 53. Shi Y, Duan ZP, Zhang X, Zhang XT, Wang GQ, Li F. downregulation of the let-7i facilitates gastric cancer invasion and metastasis by targeting COL1A1. Protein Cell 10(2), 143–148 (2019).
  Medline CASGoogle Scholar
• 54. Ao R, Guan L, Wang Y, Wang JN. Silencing of COL1A2, COL6A3 and THBS2 inhibits gastric cancer cell proliferation, migration and invasion while promoting apoptosis through the PI3k-Akt signaling pathway. J. Cell. Biochem. 119(6), 4420–4434 (2018).
  Medline CASGoogle Scholar
• 55. Wittmann T, Wilm M, Karsenti E, Vernos I. TPX2, A novel xenopus MAP involved in spindle pole organization. J. Cell Biol. 149(7), 1405–1418 (2000).
  Medline CASGoogle Scholar
• 56. Ma S, Rong X, Gao F, Yang Y, Wei L. TPX2 promotes cell proliferation and migration via PLK1 in OC. Cancer Biomark. 22(3), 443–451 (2018).
  Medline CASGoogle Scholar
• 57. Yan L, Li Q, Yang J, Qiao B. TPX2-p53-GLIPR1 regulatory circuitry in cell proliferation, invasion and tumor growth of bladder cancer. J. Cell. Biochem. 119(2), 1791–1803 (2018).
  Medline CASGoogle Scholar
• 58. Liang B, Zheng W, Fang L et al. Overexpressed targeting protein for Xklp2 (TPX2) serves as a promising prognostic marker and therapeutic target for gastric cancer. Cancer Biol. Ther. 17(8), 824–832 (2016).
  Medline CASGoogle Scholar
• 59. Tomii C, Inokuchi M, Takagi Y et al. TPX2 expression is associated with poor survival in gastric cancer. World J Surg Oncol. 15(1), 14 (2017).
  MedlineGoogle Scholar
• 60. Zeng B, Zhou M, Wu H, Xiong Z. SPP1 promotes ovarian cancer progression via Integrin beta1/FAK/AKT signaling pathway. Onco Targets Ther. 11, 1333–1343 (2018).
  MedlineGoogle Scholar
• 61. Song SZ, Lin S, Liu JN et al. Targeting of SPP1 by microRNA-340 inhibits gastric cancer cell epithelial-mesenchymal transition through inhibition of the PI3K/AKT signaling pathway. J. Cell. Physiol. 234(10), 18587–18601 (2019).
  Medline CASGoogle Scholar
• 62. Junnila S, Kokkola A, Mizuguchi T et al. Gene expression analysis identifies over-expression of CXCL1, SPARC, SPP1 and SULF1 in gastric cancer. Genes Chromosomes Cancer 49(1), 28–39 (2010).
  Medline CASGoogle Scholar
• 63. Deng R, Zhang P, Liu W et al. HDAC is indispensable for IFN-gamma-induced B7-H1 expression in gastric cancer. Clin. Epigenetics 10(1), 153 (2018).
  Medline CASGoogle Scholar
• 64. Claerhout S, Lim JY, Choi W et al. Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. PLoS ONE 6(9), e24662 (2011).
  Medline CASGoogle Scholar
• 65. Goossens JF, Bailly C. Ursodeoxycholic acid and cancer: from chemoprevention to chemotherapy. Pharmacol. Ther. 203, 107396 (2019).
  Medline CASGoogle Scholar
• 66. Wu YC, Chiu CF, Hsueh CT, Hsueh CT. The role of bile acids in cellular invasiveness of gastric cancer. Cancer Cell Int. 18, 75 (2018).
  MedlineGoogle Scholar
• 67. Rauf A, Imran M, Butt MS, Nadeem M, Peters DG, Mubarak MS. Resveratrol as an anti-cancer agent: a review. Crit. Rev. Food Sci. Nutr. 58(9), 1428–1447 (2018).
  MedlineGoogle Scholar
• 68. Xu J, Liu D, Niu H et al. Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer. J. Exp. Clin. Cancer Res. 36(1), 19 (2017).
  MedlineGoogle Scholar